Kura Oncology (KURA) Projected to Post Earnings on Wednesday

Kura Oncology (NASDAQ:KURA) is projected to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Kura Oncology Trading Up 2.0%

KURA opened at $8.48 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $12.49. The firm’s fifty day moving average is $9.27 and its two-hundred day moving average is $9.23. The firm has a market cap of $737.93 million, a PE ratio of -3.42 and a beta of 0.23.

Insider Transactions at Kura Oncology

In related news, insider Mollie Leoni sold 8,180 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $69,202.80. Following the completion of the sale, the insider directly owned 267,274 shares of the company’s stock, valued at approximately $2,261,138.04. This trade represents a 2.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Francis Burrows sold 23,726 shares of Kura Oncology stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $9.78, for a total value of $232,040.28. Following the sale, the insider directly owned 33,735 shares of the company’s stock, valued at $329,928.30. This represents a 41.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 59,794 shares of company stock valued at $537,176. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Kura Oncology by 2.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,468,522 shares of the company’s stock worth $48,396,000 after acquiring an additional 120,197 shares during the period. State Street Corp raised its stake in Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after acquiring an additional 1,587,959 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Kura Oncology by 36.6% in the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock valued at $31,816,000 after purchasing an additional 820,020 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Kura Oncology by 101.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after buying an additional 1,121,228 shares during the last quarter. Finally, Qube Research & Technologies Ltd grew its position in Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after acquiring an additional 738,761 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Zacks Research cut Kura Oncology from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 20th. UBS Group lifted their target price on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, November 14th. Leerink Partners set a $20.00 price target on Kura Oncology and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Wall Street Zen lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Barclays restated an “overweight” rating and set a $28.00 target price (up previously from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.